Coughlin Stoia Attys Seek $18M In Celexa Deal Fees
Lead counsel for the plaintiffs in a securities class action alleging that Forest Laboratories Inc. provided misleading information about the safety of its blockbuster antidepressants Celexa and Lexapro have asked for...To view the full article, register now.
Already a subscriber? Click here to view full article